.
MergerLinks Header Logo

New Deal


Announced

HeartFlow and Glenview Capital-backed Longview Acquisition II terminated a $2.4bn deal.

Financials

Edit Data
Transaction Value£1,733m
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

De-SPAC

Friendly

Majority

United States

Reverse Takeover

Health Care Services

heart health

Acquisition

Private

Cross Border

Private Equity

Failed

Merger

digital health

Medical Services

diagnosis

Synopsis

Edit

HeartFlow, a precision heart care firm, and Glenview Capital-backed Longview Acquisition II, a SPAC, terminated a $2.4bn deal. “We believe that our non-invasive, artificial intelligence-enabled, cloud-based enterprise software solution can transform cardiovascular care with risk assessment, diagnosis planning and treatment management. Importantly, we have brought together a talented group of individuals with deep expertise in technology, cardiovascular medicine, and the business of healthcare and a deep commitment to patients to deliver on this vision,” John H. Stevens, HeartFlow MD, President, CEO and Co-Founder.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US